A Randomised,Multi-Center Study of Docetaxol Plus Capecitabine or Cisplatin in Anthracycline-Pretreated Patients With Advanced Breast Cancer

Inclusion Criteria

• •age≥18y
• •KPS≥ 70
• •pathologic diagnosis of breast cancer
• •at least 1 measurable lesion as defined by modified RECIST criteria
• •screening laboratory values with the following parameters: hemoglobin:≥10.0 g/dl absolute neutrophils count:≥1.5×109/L platelet:≥100×109/L creatinine clearance rate: ≥60ml/min total bilirubin: ≤1.5 ×upper limits of normal Alkaline phosphatase,Aspartate aminotransferase and Alanine aminotransferase:≤ 2.5×upper limits of normal（≤5×upper limits of normal if liver metastasis are present)
• •signed ICF
• •for women of child bearing potential,a negative serum or urine pregnancy test result before study entry.